American Healthcare REIT Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw robust double-digit NOI growth, improved leverage, and raised full-year guidance, driven by strong segment performance and disciplined capital deployment. The acquisition pipeline remains active, with continued focus on high-quality operator partnerships.
-
Senior housing and long-term care segments are benefiting from strong demographic-driven demand, limited new supply, and robust earnings growth. Operator alignment, technology adoption, and a focus on higher-reimbursement resident mix are driving performance, while new development is expected to remain limited until at least 2027.
Fiscal Year 2025
-
Double-digit NOI and FFO growth in 2025 was driven by strong SHOP and Trilogy segment performance, disciplined acquisitions, and margin expansion. 2026 guidance calls for continued double-digit NFFO growth and robust acquisition activity, supported by ample liquidity and a strong operator network.
-
Q3 delivered 16.4% same-store NOI growth and 22% higher normalized FFO per share year-over-year, driven by strong performance in Trilogy and shop segments. Guidance for 2025 was raised, with continued portfolio expansion, disciplined capital allocation, and robust demand tailwinds.
-
Senior care demand is set to outpace supply for years, driving strong occupancy, margin, and RevPOR growth. Trilogy's operational excellence, dynamic pricing, and focus on employee retention underpin performance, while a robust acquisition pipeline and increasing AI investment support future growth.
-
Q2 2025 saw 13.9% same-store NOI growth, strong SHOP and Trilogy performance, and $255M in acquisitions. Guidance for NFFO per share and NOI growth was raised, with leverage improving to 3.7x. Favorable demographics and disciplined capital allocation support a positive outlook.
-
Senior housing fundamentals remain strong, with managed assets and regional operator focus driving double-digit NOI growth. 2025 guidance was raised on robust performance, supported by a $300M+ acquisition pipeline and disciplined balance sheet management.
-
Q1 2025 delivered sector-leading same-store NOI growth, driven by strong performance in Trilogy and SHOP segments, prompting raised full-year guidance for NOI and NFFO per share. Over $300 million in acquisitions are in the pipeline, with capital sourced from retained earnings and asset sales.
-
A diversified healthcare REIT is experiencing strong organic and external growth, driven by demographic trends and a high concentration of managed long-term care assets. The Trilogy platform is a key growth engine, with robust development, operational synergies, and industry-leading employee retention. Portfolio optimization continues through targeted acquisitions and dispositions.
Fiscal Year 2024
-
Delivered sector-leading NOI and FFO growth in 2024, driven by strong performance in Trilogy and SHOP segments and disciplined capital allocation. 2025 guidance calls for continued double-digit growth, with robust development and acquisition activity planned.
-
Q3 2024 saw robust NOI and FFO growth, driven by the Trilogy buyout, strong managed segment performance, and disciplined capital allocation. Guidance for same-store NOI and NFFO per share was raised, with leverage improved to 5.1x debt/EBITDA.
-
Q2 2024 saw 15.7% same-store NOI growth and strong performance in managed segments, prompting raised guidance for 2024. SHOP and Integrated Senior Health Campuses led with significant NOI and occupancy gains, while capital allocation remains focused on Trilogy expansion and deleveraging.
-
The presentation highlighted a diversified healthcare real estate strategy, with strong post-COVID occupancy and margin growth driven by demographic trends and limited new supply. Trilogy, the largest investment, stands out for operational excellence and labor management. The main capital focus is acquiring the remaining stake in Trilogy, with a disciplined approach to leverage and dividends.